Medical/Pharmaceuticals

HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases,...

2026-02-13 14:04 9260

Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now available at its Hong Kong Science Park laboratory. Since the...

2026-02-13 14:00 5763

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2026-02-13 08:00 8843

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/...

2026-02-13 08:00 12882

Datasea Reports Second Fiscal Quarter 2026 Results

Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalizati...

2026-02-12 22:20 15853

Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide

Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- On February 8, at the 2026 China New Drug Source Innovation Forum inShanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten...

2026-02-12 22:00 8281

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

* Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) in...

2026-02-12 20:00 6494

First clinical success! Yuanhua Tech, with its orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, breaks into the high-end medical equipment market

HONG KONG, Feb. 12, 2026 /PRNewswire/ -- On February 11, the orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, which was 100% homemade by Yuanhua Robotics, Perception and AI Technologies Ltd. (hereinafter referred to as "Yuanhua Tech"), saw its first clinic...

2026-02-12 19:34 4476

EDAN Connects Clinical Practice and Innovation at 2026 WHX Dubai and WHX Labs Dubai

DUBAI, UAE, Feb. 12, 2026 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ) participated in WHX Dubai (Formerly Arab Health) and WHX Labs Dubai (Formerly Medlab Middle East), presenting a comprehensive portfolio of medical solutions across multiple clinical dis...

2026-02-12 17:27 7330

Berlin Heals Successfully Raises Over 10M USD to Expand the New Less Invasive Approach to More Heart Failure Patients

ZUG, Switzerland, Feb. 12, 2026 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors. Th...

2026-02-12 16:00 5693

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Associa...

2026-02-12 15:01 6333

Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmona...

2026-02-12 12:18 8270

WuXi Vaccines Receives Brazil's ANVISA GMP Certification

SUZHOU, China, Feb. 11, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish f...

2026-02-12 11:48 6881

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceutica...

2026-02-11 19:31 8313

Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications

HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139,  a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These i...

2026-02-11 17:01 8267

ArisGlobal Announces XDI NavaX Data Intelligence, Three New Agents, and NavaX Translation

MADRID, Feb. 11, 2026 /PRNewswire/ -- ArisGlobal , an AI-first technology company at the forefront of Life Sciences and creator ofLifeSphere®,

2026-02-11 16:55 6501

PharmaResearch Announces Supply Agreement for Rejuran in Brazil

SEONGNAM, South Korea, Feb. 11, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEOJihoon Sohn), a leading regenerative medicine company, announced that it has entered into an exclusive supply agreement for Rejuran with DermaDream, a Brazilian aesthetic company, as part of its preparations for ent...

2026-02-11 14:54 6776

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

-   Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. -   In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once...

2026-02-11 07:15 10085

Landmark decision by the World Health Organization's Executive Board to approve a WHA resolution on hemophilia and other bleeding disorders

MONTREAL, Feb. 10, 2026 /PRNewswire/ -- On February 3rd, 2026, the Executive Board of the World Health Organization (WHO), in a landmark decision, approved a Member-State led resolution onGlobal Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders, which will no...

2026-02-10 23:00 5023

On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully

SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. Th...

2026-02-10 21:07 7906
1 ... 90919293949596 ... 645